Cowen analyst Ritu Baral reiterated an Outperform rating on Sarepta Therapeutics (NASDAQ:SRPT) with a price target of $19, as the company announced data through Week 168 …
In a research report sent to investors today, Canaccord Genuity analyst Adam Walsh initiated coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) with a …
In a research report released this morning, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) with a $22 price …